Prior fluconazole exposure as an independent risk factor for fluconazole resistant candidosis in HIV positive patients: a case-control study

Jonathan D Cartledge, Jennifer Midgley, Brian G Gazzard

Objective: To determine if prior fluconazole exposure was an independent risk factor for fluconazole resistant candidosis in HIV positive patients.

Methods: Twenty five HIV positive cases with fluconazole resistant oral candidosis were matched by CD4 lymphocyte count and time since first episode of candidosis to 25 HIV positive controls with susceptible candidosis. For each individual a history of prior azole prescription was compiled from computerised pharmacy records and review of case notes.

Results: The total days of prior azole therapy prescribed was significantly greater for cases than controls. These differences were attributable to prescriptions for secondary prophylaxis against recurrent candidosis, the cases having received significantly longer continuous azole prophylaxis than controls, with no difference in days of prior azole therapy remaining between the two groups if prophylactic prescriptions were excluded. The total cumulative dose of fluconazole received was significantly higher for cases than controls, though mean daily fluconazole doses did not differ significantly between the two groups.

Conclusion: Even after controlling for degree of immunosuppression and duration of recurrent candidosis, the association between prior azole exposure and fluconazole resistant candidosis remains significant and largely reflects differences in the prescription of secondary antifungal prophylaxis.

(Genitourin Med 1997;73:471–474)

Keywords: fluconazole; candidosis; HIV; risk factor
Table 1  Comparison of prior antifungal prescription in cases with fluconazole resistant candidosis and controls with susceptible candidosis

<table>
<thead>
<tr>
<th></th>
<th>Cases</th>
<th>Controls</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total days of priorazole therapy</td>
<td>336 (114–1283)</td>
<td>87 (21–483)</td>
<td>&lt; 0·0001</td>
</tr>
<tr>
<td>Proportion of days since first candidosis prescribed azole therapy</td>
<td>56% (22–96%)</td>
<td>12% (0·05–65%)</td>
<td>&lt; 0·0001</td>
</tr>
<tr>
<td>Months of continuous azole prophylaxis</td>
<td>9 (4–41)</td>
<td>0 (0–4)</td>
<td>&lt; 0·0001</td>
</tr>
<tr>
<td>Fluconazole cumulative dose (mg)</td>
<td>16 500 (3500–119 000)</td>
<td>2900 (0–105 600)</td>
<td>&lt; 0·0001</td>
</tr>
<tr>
<td>Mean daily fluconazole dose (mg)*</td>
<td>106 (48–289)</td>
<td>92 (0–360)</td>
<td>0·46</td>
</tr>
<tr>
<td>Itraconazole cumulative dose (mg)</td>
<td>9600 (0–42000)</td>
<td>2100 (0–14 800)</td>
<td>0·07</td>
</tr>
<tr>
<td>Mean daily itraconazole dose (mg)*</td>
<td>200 (0–400)</td>
<td>200 (0–400)</td>
<td>0·40</td>
</tr>
<tr>
<td>Ketoconazole cumulative dose (mg)</td>
<td>22 400 (0–173 600)</td>
<td>8400 (0–34 400)</td>
<td>0·07</td>
</tr>
<tr>
<td>Mean daily ketoconazole dose (mg)*</td>
<td>386 (0–467)</td>
<td>309 (0–400)</td>
<td>0·68</td>
</tr>
<tr>
<td>Cumulative fluconazole dose until 1 month before fluconazole failure (mg)</td>
<td>11 700 (200–116 900)</td>
<td>2900 (0–105 600)</td>
<td>0·001</td>
</tr>
<tr>
<td>Cumulative Fluconazole dose until 1 year before fluconazole failure (mg)</td>
<td>9800 (0–36 400)</td>
<td>1400 (0–13 800)</td>
<td>0·0001</td>
</tr>
</tbody>
</table>

*The mean daily dose of each azole prescribed for each patient was calculated and the median and range for the two groups shown.

X 10⁶/l, if that of the case was 20–150 cells X 10⁶/l, and within 50 cells X 10⁶/l if that of the case was > 150 cells X 10⁶/l.

SUSCEPTIBILITY TESTING

In vitro susceptibility testing was performed using a technique devised by Odds,¹ which has been shown to be both sensitive and specific as an indicator of clinically significant resistance to fluconazole.² Briefly, this microplate technique measures the growth of an isolate in a well of CYG (pancreatic casein digest/yeast extract/glucose) broth containing a single concentration of fluconazole (10⁻⁶ M: 3 μg/ml) and the growth achieved by the same isolate in control well of CYG broth containing no antifungal. The growth in fluconazole is expressed as a percentage of that in the control well to give a value of relative growth in fluconazole. Isolates achieving relative growth in fluconazole exceeding 88% are associated with candidosis unresponsive to fluconazole in vivo.³

STATISTICAL ANALYSIS

All parametric variables were compared using Student’s t test. Non-parametric variables were compared using the Mann-Whitney U test.

Results

The study sample consisted of 25 patients with fluconazole resistant candidosis and 25 patients with fluconazole susceptible candidosis. CD4 count at time of susceptibility assessment was matched between the two groups, and CD4 count at time of first candidosis did not significantly differ between the two groups (cases, mean 128 cells X 10⁶/l; controls, mean 139 cells X 10⁶/l (p = 0·779).

The total number of days of azole therapy prescribed before the date of susceptibility evaluation and the proportion of days since first candidosis upon which antifungals were received were significantly longer for the cases than for the controls (table 1) This difference in the number of days of prior azole therapy was largely due to prescriptions for secondary prophylaxis rather than treatment of acute attacks, the patients with fluconazole resistant candidosis having received significantly longer continuous azole prophylaxis than those with responsive thrush (table 1). When all prescriptions for secondary prophylaxis (defined as prescription for more than 28 days’ treatment) were deducted from the total duration of azole exposure, the median number of days of acute therapy for both cases and controls was the same (84 days).

The total cumulative dose of fluconazole received since first candidosis was significantly higher for those developing fluconazole resistant candidosis than for the control group, even if the fluconazole prescribed in the month or year before susceptibility assessment was excluded from the analysis. There was no difference in the mean daily dose of fluconazole prescribed to the two groups. Although the median total cumulative doses of itraconazole and ketoconazole were higher for the cases than controls, this trend was not statistically significant. Since the prior azole exposure of cases was counted up until the first date of clinical fluconazole failure, the cumulative doses of the other azoles precede this event and do not represent treatment changes in response to fluconazole resistance. None of the patients, cases or controls, had received topical azole therapy.

Concurrent antibiotic therapies were similar for the two groups. All patients were receiving prophylaxis against Pneumocystis either in the form of co-trimoxazole (10 cases, 14 controls), dapsone (10 cases, seven controls), or inhaled pentamidine (five cases, four controls). At the time of sampling the majority (17 cases, 16 controls) were taking no other antibacterial agents, though nine (three cases and six con-

Table 2  Comparison of characteristics of patients infected with fluconazole resistant Candida albicans alone and those infected with fluconazole resistant non-albicans species, either alone (one case) or mixed with C albicans (seven cases)

<table>
<thead>
<tr>
<th>Patients with resistant pure Candida albicans infection (n = 17)</th>
<th>Patients with non-albicans species isolated (n = 8)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median CD4 lymphocyte count cells X 10⁶/l at time of detection of resistance</td>
<td>9 (1–59)</td>
</tr>
<tr>
<td>Median total days of prior azole therapy prescribed</td>
<td>378 (200–1149)</td>
</tr>
<tr>
<td>Total cumulative dose of prior fluconazole (mg)</td>
<td>20 400 (3500–61 600)</td>
</tr>
</tbody>
</table>
trols) were co-prescribed treatment for mycobacterial infection and eight (five cases, three controls) were given routine antibacteri- als.

For those patients who developed fluconazole resistant candidiasis, there was a significant positive correlation between CD4 count at time of fluconazole failure and days of prior azole exposure \( (r = 0.45; p = 0.02) \) or total cumulative dose of fluconazole \( (r = 0.7, p < 0.001) \).

Median fluconazole relative growth (growth in fluconazole containing medium expressed as a percentage of that in medium containing no antifungal) was 97% (range 85–118%) for cases and 41% (range 2–74%) for controls. Of the 25 patients with fluconazole resistant candidiasis, 17 were infected with fluconazole resistant strains of Candida albicans alone, one with C. glabrata alone, and seven with mixtures of C. albicans and non-albicans species (C. krusei in three cases; Saccharomyces cerevisiae in two cases, C. tropicalis in one case, and C. glabrata in one case). Although the patients with non-albicans species present appeared to have higher median CD4 counts, lower duration of prior azole exposure and lower cumulative doses of fluconazole than those with only C. albicans isolated, none of these differences were statistically significant (table 2).

Discussion

Although all case-control studies have the potential for hidden biases, the differences observed in this study were striking and the two groups were well matched. The immune status of the two groups would appear similar since although only matched for CD4 count at time of susceptibility assessment they also had similar CD4 counts at time of initial episode of candidosis.

The most relevant finding was that the total cumulative dose of fluconazole received was considerably higher in the group with fluconazole resistance than in the controls, and that this was entirely due to differences in the prescription of continuous fluconazole prophylaxis at doses of 50–100 mg/day. The higher cumulative doses of fluconazole received by those developing resistance did not appear to be attributable to increasing requirements due to intermediate resistance just before drug failure, since the differences remained significant even if the final month or year ofazole therapy before drug failure were excluded from the analysis. The patients with fluconazole resistance were exposed to higher doses of other azoles, but not significantly so. The risk of fluconazole resistance may be specifically linked to exposure to this azole; however, in individual cases such resistance occurred after little exposure to fluconazole and greater prior treatment with the other azoles.

Our findings build upon the findings of Johnson et al., who demonstrated that HIV positive patients with lower CD4 counts and histories of continuous azole therapy were more inclined to develop fluconazole resistance than less immunosuppressed individuals receiving short courses of antifungal therapy. By matching controls to our cases by CD4 count and duration of recurrent candidosis, the impact of prior azole exposure is more accurately delineated, and shown to be independently related to the emergence of resistance. The retrospective nature of our study makes it possible that other factors may contribute to the differences between the two groups. Exposure to antibacterials, which might encourage candidosis or to agents such as rifampicin or rifabutin which might lessen the efficacy of azole therapy were compared for the cases and controls and found to be similar. In this retrospective study it was not possible to accurately compare the number of episodes of clinical candidosis experienced by each group. If the cases had suffered more frequent recurrent candidosis or more severe symptoms they might require more treatment, or be more inclined to request continuous therapy. These potential factors require prospective evaluation.

The CD4 counts of the resistant cases correlated positively with prior cumulative fluconazole dose, that is those with lower CD4 counts had received less prior fluconazole before developing resistance than those with higher counts. Thus if increasing prior azole exposure is a risk factor for fluconazole resistance, as this study suggests, it would appear that the dose required to predispose to resistance may be lower for more immunosuppressed individuals.

There is a suggestion that non-albicans species resistant to fluconazole were more likely to occur in individuals with higher CD4 counts after less exposure to fluconazole. These differences were not significant, and risk factors for fluconazole resistance due to C. albicans compared with non-albicans species are thus being evaluated in a larger study.

Thus, primary or secondary prophylaxis with fluconazole at doses of 50–100 mg/day should only be initiated after careful consideration as this may encourage the development of resistance. The primary prophylaxis of serious systemic mycoses, particularly cryptococcosis is mandatory. The fluconazole doses used in such situations are higher (200–400 mg/day) than the doses given to prevent relapsing candidosis for patients in our study. How a higher dosed prophylactic regimen might affect the emergence of resistant candidosis has not yet been evaluated.

A recent study has indicated that fluconazole 200 mg/day is effective as primary prophylaxis against cryptococcosis, although there was no survival benefit, and the risk of developing such systemic mycoses is low. Breakthrough candidosis was common in this study, and although data regarding susceptibility of Candida species isolated have not been presented fluconazole resistance is a likely cause, if non-compliance with study medication is excluded.

In conclusion, prophylaxis against recurrent candidosis with low doses of fluconazole would appear ill advised since this is associated with the emergence of resistant candido-
sis. Higher doses may have an impact upon other systemic mycoses though the local risk of such infections needs to be taken into consideration and the risk of resistance emerging with such regimens remains unevaluated.

We wish to thank the Janssen Research Foundation for their part funding of JM’s post.